학술논문

Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Document Type
Article
Source
Leukemia & Lymphoma. Mar2023, Vol. 64 Issue 3, p742-745. 4p.
Subject
*HEMATOPOIETIC stem cell transplantation
*HODGKIN'S disease
*SALVAGE therapy
Language
ISSN
1042-8194
Abstract
It is important to note that the BvB regimen was administered exclusively in the outpatient setting, and more interestingly, none of the patients from the BvB-group required admission/hospitalization during the treatment period. .05 Number of patients with bulky disease (>=10 cm)110 Number of patients required hospitalization30300 Days of admission10 (0-38)13 (6-36)0Response in whole patients Complete21 (45%)11 (36%)10 (62%)0 Since a variety of conditioning regimens were used among the autografted patients and two patients (both from platinum-based group) received Bv as maintenance post ASCT, the overall effect of BvB vs. the platinum-based salvage regimens cannot be accurately assessed. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and "bridge" to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma. [Extracted from the article]